Hormone Replacement Therapy in Patients with Heart Disease

Contraindications and Risks

Women taking HRT who have documented heart disease show a significant 52% increase in cardiovascular events in the first year compared to placebo, and the American Heart Association recommends against using HRT for primary prevention of cardiovascular disease 1
The American Heart Association and other guidelines recommend that hormone replacement therapy (HRT) should not be initiated for women discovered to have coronary artery disease, and discontinuation should be strongly considered for those already on HRT who develop CAD, due to increased risk of cardiovascular events and potential harm 2, 1

Non-hormonal pharmacologic options such as SNRIs like venlafaxine can be used for vasomotor symptoms, and gabapentin for hot flashes and associated irritability 3
Non-pharmacologic approaches such as regular aerobic and resistance exercise, environmental modifications, dietary changes, and acupuncture can be used to manage menopausal symptoms 3

Immediate discontinuation of HRT is recommended during hospitalization for acute coronary events, periods of immobilization, and prior to surgery associated with thromboembolism risk, and discontinuation is strongly recommended for women with stable CAD who have been on HRT for >1-2 years 1
If a woman has been on HRT for more than 1-2 years and wishes to continue for another compelling indication, she should understand the increased risk of cardiovascular events and breast cancer (with combination therapy) or stroke (with estrogen alone) 2
Discontinuation of HRT is recommended, but if not feasible, VTE prophylaxis should be considered during the period of immobilization 1, 4

Initiating HRT for cardioprotection is directly contradicted by randomized trials showing no benefit and potential harm, and HRT should not be initiated for secondary prevention of cardiovascular disease, as evidence from randomized controlled trials shows no cardiovascular benefit and possible early increased risk when starting HRT in women with established atherosclerosis 2, 1, 4

The American College of Cardiology recommends that all patients with CAD, regardless of HRT status, should receive standard evidence-based therapies, including antiplatelet therapy, beta-blockers, lipid management, ACE inhibitors, and lifestyle modifications 5
Antiplatelet therapy should include aspirin 75-325 mg daily, or clopidogrel 75 mg daily for patients with aspirin contraindications 5
Lipid-lowering agents should be used for LDL cholesterol >100 mg/dL, with more aggressive lipid lowering for post-ACS patients with LDL >125 mg/dL 5
ACE inhibitors should be used for patients with heart failure, left ventricular dysfunction, hypertension, or diabetes 5
Lifestyle modifications should include smoking cessation, regular exercise, dietary changes, and weight optimization 4, 5

Low-risk medically treated patients and revascularized patients should return for follow-up in 2-6 weeks, while higher-risk patients should return within 14 days 2, 5
Patients with recurrent unstable angina or severe chronic stable angina despite medical management should undergo coronary angiography 2, 5

Assuming all HRT formulations carry equal risk is incorrect, as transdermal formulations may have a better cardiovascular safety profile than oral formulations if HRT must be continued for other compelling reasons 3
Neglecting standard CAD therapies is a common mistake, as focus should remain on evidence-based therapies for CAD management regardless of HRT status 2, 5
Continuing HRT during hospitalization increases risk of venous thromboembolism, particularly during immobilization 1